{"filings":[{"id":1277601,"accession_number":"0001104659-26-077790","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2026-06-25T20:30:12+00:00","items":["5.07","9.01"],"status":"ready","headline":"Protalix shareholders approve director elections, executive compensation, stock plan increase, auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected eight directors: each with >28.7M votes; broker non-votes 10.7M for each.","Advisory approval of executive compensation: 28.4M for, 6.7M against, 0.2M abstain.","Approved stock plan amendment increasing authorized shares from 17.5M to 21.0M shares (28.2M for, 7.0M against).","Ratified Kesselman & Kesselman (PwC) as independent auditor for FY2026: 42.96M for, 2.0M against, 1.0M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":563596,"accession_number":"0001104659-26-064850","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2026-05-21T11:03:16+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protalix BioTherapeutics files corporate presentation; no material new information","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing reports posting of May 2026 corporate presentation to company website under Item 7.01.","Exhibit 99.1 contains only title slides with general corporate description and date change from June 2024 to May 2026.","No financial results, guidance updates, or operational milestones disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":49881,"accession_number":"0001104659-26-059749","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2026-05-13T10:57:15+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protalix BioTherapeutics Reports First Quarter 2026 Financial Results and Reaffirms Guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Received $25 million milestone from Chiesi following European Commission approval of Elfabrio 2 mg/kg every-4-weeks dosing regimen.","PRX-115 Phase 2 RELEASE study for uncontrolled gout continues; top-line results expected second half of 2027.","Reaffirms 2026 revenue guidance of $78.0-$83.0 million including $25 million milestone; Elfabrio sales $33-$35 million, Elelyso $20-$23 million.","Cash and equivalents $51 million as of March 31, 2026; no outstanding debt or warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100168,"accession_number":"0001104659-26-029846","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protalix reports FY2025 results; EC approves Elfabrio E4W regimen triggering $25M milestone","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["EC approved Elfabrio 2mg/kg every-4-weeks dosing for stable adults with Fabry in EU; $25M milestone from Chiesi triggered.","Total 2026 revenue guided to $78M-$83M including milestone; Elfabrio sales $33-35M, Elelyso $20-23M.","Phase 2 RELEASE trial for PRX-115 (uncontrolled gout) actively enrolling; top-line data expected H2 2027.","Company expects cash balance ~$50M by April 2026 with no outstanding debt or warrants.","No specific FY2025 financial numbers disclosed in the press release; focus on business and regulatory milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100167,"accession_number":"0001104659-26-024975","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EC approves Elfabrio every-4-weeks dosing; Protalix gets $25M milestone","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["European Commission approved 2 mg/kg every-4-weeks regimen for Elfabrio in stable adult Fabry patients.","Decision follows positive CHMP opinion; dosing reduces infusion frequency from every-2-weeks.","Protalix entitled to a $25 million regulatory milestone payment from Chiesi upon EC approval.","US FDA-approved dosing remains 1 mg/kg every 2 weeks; not affected by EU decision.","BRIGHT study (PB-102-F50) and extension study supported the alternative dosing regimen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100166,"accession_number":"0001104659-26-013498","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protalix BioTherapeutics posts February 2026 corporate presentation to website; no material new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed Form 8-K indicating a corporate presentation was posted on February 11, 2026.","Exhibit 99.1 consists solely of a title slide with no specific financial or pipeline updates.","No new guidance, clinical data, or business developments were provided in the furnished exhibit.","Investors would need to access the full presentation on the company website for details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.01,"calibrated_materiality_score":0.01,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100165,"accession_number":"0001104659-26-008410","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Protalix gets positive CHMP opinion for every-4-week dosing of Elfabrio in EU; $25M milestone if EC approves","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP issued positive opinion for 2 mg/kg every-4-weeks dosing regimen of Elfabrio for stable Fabry adults.","Positive opinion follows re-examination; EC decision expected by March 2026.","Protalix eligible for $25M regulatory milestone from Chiesi if EC approves the regimen.","The extended dosing interval aims to reduce treatment burden; regimen not approved in U.S.","BRIGHT study and ongoing extension with median exposure ~6 years supported the opinion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100164,"accession_number":"0001104659-26-000393","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protalix provides business update; PRX-115 Phase 2 IND effective, gout market focus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PRX-115 Phase 1 data show rapid, durable urate lowering lasting 12 weeks at higher doses; Phase 2 IND effective.","Fabry drug Elfabrio launched through Chiesi; CHMP negative opinion on E4W dosing under appeal, outcome Q1 2026.","Fabry market projected $3.4B by 2030; Elfabrio target capture 15-20% share.","Elelyso revenue continues via Pfizer and Fiocruz partnerships.","New renal pipeline includes PRX-119 (long-acting DNase I) and Secarna RNA collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116502,"accession_number":"0001104659-25-110821","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protalix Q3 revenue flat at $17.9M; net income down to $2.4M; PRX-115 phase 2 IND effective","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenue flat at $17.9M; net income $2.4M ($0.03 EPS) vs $3.2M ($0.04) in Q3 2024.","Nine-month 2025 revenue $43.6M (+24% YoY); net loss improved to $1.1M from $3.6M.","PRX-115 IND effective; phase 2 trial for uncontrolled gout planned for late 2025.","Chiesi requested re-examination of CHMP negative opinion on Elfabrio 2 mg/kg E4W; 1 mg/kg E2W still approved.","Cash and equivalents $29.4M at Sep 30, 2025; sufficient for at least 12 months."],"consensus_eps_estimate":0.0556,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":43622000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116501,"accession_number":"0001104659-25-105594","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Protalix and Chiesi request re-examination of negative EMA opinion on Elfabrio E4W dosing regimen","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP issued negative opinion on Elfabrio 2 mg/kg every-4-weeks dosing regimen; re-examination requested.","Existing EU marketing authorization for every-2-weeks regimen remains in effect pending outcome.","Approved E2W dosing regimen unchanged; companies committed to addressing Fabry community needs.","Re-examination process underway; timeline for final EC decision not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116500,"accession_number":"0001104659-25-100264","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Protalix and Chiesi receive CHMP negative opinion on every-4-week dosing for Elfabrio in EU","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP issued negative opinion for 2 mg/kg every 4 weeks dosing of Elfabrio (pegunigalsidase alfa) for Fabry disease.","Currently approved dosing regimen of 1 mg/kg every 2 weeks remains unchanged in the EU.","Decision based on BRIGHT trial and modeling; data insufficient to conclude similar efficacy.","Chiesi and Protalix express disappointment but reaffirm commitment to Fabry community.","No financial guidance or other material impact disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132953,"accession_number":"0001104659-25-081924","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Protalix amends at-the-market offering agreement to reflect new S-3 registration","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["On August 22, 2025, amended Sales Agreement with H.C. Wainwright & Co., LLC.","Amendment updates the registration statement to Form S-3 (No. 333-286802).","At-the-market equity offering program terms remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132952,"accession_number":"0001558370-25-011468","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protalix Q2 2025: Revenue $15.4M (+16% YoY), net income $164K; CFO transition, PRX-115 trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from goods $15.4M (+16% YoY); net income $164K vs $2.2M loss, EPS $0.00.","Elfabrio sales to Chiesi up $8M; EMA reviews label extension for every-4-weeks dosing.","CFO Eyal Rubin steps down Aug 24, replaced by Gilad Mamlok; transition through October.","PRX-115 Phase 2 for uncontrolled gout planned H2 2025; first patient enrollment Q4 2025.","Cash $33.4M; R&D doubled to $6M on PRX-115 prep; added to Russell 2000/3000 indexes."],"consensus_eps_estimate":0.0303,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":25771000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132951,"accession_number":"0001558370-25-009989","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Protalix BioTherapeutics resolves stockholder class action; pays $160k fees","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Plaintiff Kevin Mathew Thomas filed suit on March 10, 2025, challenging certain bylaws provisions under Delaware law.","On May 8, 2025, the Board amended the challenged bylaws, rendering plaintiff's claims moot.","Company agreed to pay $160,000 in fees and expenses to plaintiff's counsel; no admission of wrongdoing.","Court entered dismissal with prejudice as to plaintiff on July 23, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132950,"accession_number":"0001558370-25-009308","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Protalix appoints Gilad Mamlok as SVP & CFO effective Aug 24, 2025, succeeding Eyal Rubin","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gilad Mamlok appointed Senior VP & CFO, effective August 24, 2025.","He succeeds Eyal Rubin, who resigned to pursue other opportunities.","Mamlok brings 30 years experience, previously CFO of TytoCare and Sol-Gel Technologies.","He receives monthly base salary of NIS 81,000 (~$24,066) plus discretionary bonus and options for 597,990 shares at $1.45.","Options vest over 3 years, accelerated upon change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149506,"accession_number":"0001558370-25-008922","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Protalix shareholders elect eight directors, approve advisory compensation, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Eight director nominees elected with for votes ranging from 21.3M to 22.6M; broker non-votes ~12.7M.","Non-binding advisory vote on named executive officer compensation passed: 16.4M for, 7.5M against, 0.4M abstain.","Ratification of Kesselman & Kesselman (PwC Israel) as independent auditor for 2025 approved: 34.9M for, 1.6M against.","Broker non-votes of ~12.7M present on director election and compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149505,"accession_number":"0001558370-25-007060","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protalix BioTherapeutics Q1 revenue up 170% to $10.0M, net loss narrows to $3.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues from selling goods $10.0M, up 170% YoY, driven by $5.9M increase in sales to Pfizer.","Net loss $3.6M ($0.05/sh) vs $4.6M ($0.06/sh) in Q1 2024; cash $34.7M.","Phase II trial of gout candidate PRX-115 expected to start H2 2025 after positive FIH results.","R&D expenses $3.5M (+21% YoY) due to clinical pipeline advancement; SG&A down 16% to $2.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":10113000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149504,"accession_number":"0001558370-25-005275","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Protalix CFO Eyal Rubin resigns; to serve six-month transition through Oct 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eyal Rubin, Sr. VP & CFO, provided six months' notice on April 21, 2025 to pursue other opportunities.","He will continue in his role for the six-month period and assist with transition.","Compensation Committee agreed to full salary, benefits, and equity incentives during the period.","Upon termination, he will receive two months' salary severance and full accelerated vesting of unvested equity.","No successor has been appointed; earlier termination possible with mutual agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168577,"accession_number":"0001558370-25-003143","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Protalix increases ATM equity offering capacity by $20M for general corporate purposes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment with H.C. Wainwright increases ATM offering capacity by $20M in aggregate gross sales price.","Net proceeds will be used for general corporate purposes, including working capital and clinical trials.","Prospectus supplement filed to register additional shares under existing shelf registration statement.","No shares were previously available for sale under the existing Sales Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168576,"accession_number":"0001558370-25-003036","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protalix FY 2024: Record product revenue $53M (+31%), net income $2.9M; debt-free","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from goods $53.0M (+31% YoY), driven by Chiesi sales (+$11.8M); total revenue $53.4M vs $65.5M in 2023.","Net income $2.9M ($0.04/sh diluted) vs $8.3M ($0.12/sh basic) in 2023; lower due to absence of $20M milestone.","Cash $34.8M; convertible notes fully repaid Sep 2024; no warrants remaining after March 2025 expiration.","PRX-115 (gout) phase I completed; phase II expected H2 2025; EMA validated less frequent dosing for pegunigalsidase alfa."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185691,"accession_number":"0001558370-24-016505","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2024-12-31T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Protalix BioTherapeutics amends bylaws to raise special meeting threshold to 25% and remove written consent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders now need 25% beneficial ownership (up from 10%) to call a special meeting.","Company secretary must set meeting date at least 30 days after request (was 10 days).","Stockholders can no longer act by written consent in lieu of a meeting.","Exclusive forum provisions added: Delaware Chancery Court for state claims, federal courts for Securities Act claims.","Enhanced procedural and disclosure requirements for stockholder proposals and director nominations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185690,"accession_number":"0001558370-24-016445","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protalix repays all convertible notes, becomes debt-free; EMA validates Fabry drug dosing variation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repaid in full all outstanding convertible notes, making company debt-free.","EMA validated Chiesi's variation submission for pegunigalsidase alfa every-four-week dosing in EU.","Completed Phase I trial of PRX-115 for uncontrolled gout; Phase II planned H2 2025.","Revenue streams from Elfabrio, Elelyso, and Uplyso growing; full operations maintained despite Israel conflict.","Fine-tuned R&D strategy on renal rare diseases and plant-based drug delivery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185689,"accession_number":"0001558370-24-015608","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protalix Q3 net income $3.2M, revenue up 75%; PRX-115 Phase I positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from goods $17.8M (+75% YoY); net income $3.2M vs loss $1.9M in Q3 2023; EPS $0.04 basic.","PRX-115 Phase I completed all eight cohorts; single dose lowered uric acid below 6.0 mg/dL for up to 12 weeks at highest doses.","PRX-115 well-tolerated: 25% of treated subjects reported mild-to-moderate AEs; one resolved anaphylactic reaction.","Cash $27.4M at Sept 30; repaid 7.5% senior secured convertible notes due Sept 2024 from available cash.","Planning phase II trial of PRX-115 in gout patients, initiation expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":35181000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185688,"accession_number":"0001558370-24-013664","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protalix to present Phase I PRX-115 data in late-breaking poster at ACR Convergence 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PRX-115 is a recombinant PEGylated uricase for uncontrolled gout treatment.","Data from Phase I trial will be presented at ACR Convergence 2024 (Nov 14-19, Washington, D.C.).","Poster session: Monday Nov 18, 10:30 AM-12:30 PM EST; abstract number L05.","Abstract available on ACR abstracts website; poster to be posted on Protalix website.","No clinical results disclosed; presentation details only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202257,"accession_number":"0001558370-24-012133","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protalix Q2 2024: revenue $13.5M, net loss $2.2M; PRX-115 Phase I topline expected Q3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q2 2024 revenue $13.5M vs $35.1M in Q2 2023; net loss $2.2M ($0.03/sh) vs net income $19.3M ($0.29/sh).","Product revenue from goods $13.3M (-12% YoY); license & R&D revenue $0.2M (vs $20.0M milestone from Chiesi in Q2 2023).","PRX-115 (uncontrolled gout) Phase I: positive topline from first 7 cohorts; 8th cohort dosed, full results expected Q3 2024.","Cash, cash equivalents and short-term bank deposits $45.0M at June 30, 2024; post-quarter collected $4.6M from Pfizer, $2.3M from Brazil.","R&D expenses decreased 33% to $3.0M due to completion of Fabry clinical program and Elfabrio regulatory processes."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":17222000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218343,"accession_number":"0001558370-24-009567","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Stockholders approve increase in share reserve for 2006 Stock Incentive Plan to 17.5M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Seven directors elected; CEO Dror Bashan among those with over 22M for votes.","Advisory vote on executive compensation passed: 17.0M for, 9.88M against.","Stock plan amended: shares available increased from ~12.5M to 17,475,171.","Kesselman & Kesselman (PwC Israel) ratified as auditor for fiscal 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218342,"accession_number":"0001558370-24-007692","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protalix Q1 net loss $4.6M; PRX-115 phase I positive, adds cohort","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from goods $3.7M (-27% YoY); license/R&D services $0.1M (-98%) as Elfabrio obligations completed.","Net loss $4.6M ($0.06/shr) vs $3.1M loss ($0.05) YoY; cash $48.5M at quarter end.","PRX-115 phase I: dose-dependent uric acid reduction, well-tolerated; expanding to 8th cohort, planning phase II.","R&D expenses down 50% to $2.9M on completion of Fabry program and Elfabrio regulatory filings."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":3748000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238275,"accession_number":"0001558370-24-003160","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protalix reports 2023 net income $8.3M vs loss; Elfabrio approvals, $20M milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from goods $40.4M (+60% YoY); license/R&D services $25.1M (+13%).","Net income $8.3M ($0.12 diluted EPS) vs net loss $14.9M in 2022.","Cash $44.6M at year-end; Elfabrio approved in US, EU, UK, Switzerland, Israel.","$20M milestone from Chiesi triggered by FDA approval; $17.5M Elfabrio sales post-approval.","PRX-115 Phase I fully enrolled; results expected Q2 2024. New chairman appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255762,"accession_number":"0001558370-23-020006","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2023-12-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protalix updates on Elfabrio approvals, PRX-115 Phase I progress, and pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elfabrio (Fabry disease) approved by FDA and EMA; launched in US, EU, UK via Chiesi partnership.","Phase I trial of PRX-115 (gout) completed 7th cohort with 56 patients dosed; completion expected Q2 2024.","Preclinical development advancing for PRX-119 (DNase I for NETs-related diseases).","CEO acknowledges ongoing challenges in Israel, reaffirms commitment to operations and pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255761,"accession_number":"0001558370-23-017657","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protalix Q3 revenues from goods up 16% to $10.2M; net loss narrows to $1.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues from selling goods $10.2M (+16% YoY), driven by Elfabrio sales to Chiesi after FDA/EMA approvals.","License and R&D service revenues fell 96% to $0.2M as extension studies transferred to Chiesi.","Net loss improved to $1.9M ($0.03 basic EPS) vs $3.6M loss ($0.07 EPS) in Q3 2022.","Cash and equivalents $41.0M; PRX-115 Phase I for gout enrolled 32 patients, results expected mid-2024.","Regulatory: UK MHRA and Swissmedic approved Elfabrio; Dr. Eliot Forster appointed Board Chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":55008000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273186,"accession_number":"0001558370-23-015635","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2023-09-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Protalix appoints Eliot Richard Forster as Chairman; Zeev Bronfeld retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Forster appointed Chairman and independent director effective Sept 14, 2023; also joins Nominating Committee.","Zeev Bronfeld retires as Chairman after nearly three decades; cites recent drug approval as transition point.","Forster receives 10-year option for 85,715 shares vesting quarterly over 3 years and $70,000 annual fee.","Forster is non-executive chairman of Avacta Group and director of Immatics NV; former CEO of F-Star Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273185,"accession_number":"0001558370-23-013481","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protalix reports Q2 net income of $19.3M on Elfabrio sales and $20M milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from goods $15.1M (+344% YoY) driven by Elfabrio sales to Chiesi after FDA/EMA approvals.","License & R&D revenue $20.0M (+270% YoY) from $20M regulatory milestone payment from Chiesi.","Net income $19.3M ($0.29 basic EPS) vs net loss of $5.3M in Q2 2022; cash $48.2M.","Elfabrio received US FDA (May 10) and EU (May 5) approval for adult Fabry disease; launched in US by Chiesi.","PRX-115 phase I trial for severe gout ongoing; 16 patients dosed to date."],"consensus_eps_estimate":null,"consensus_eps_actual":0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":44663000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273184,"accession_number":"0001558370-23-011868","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Protalix BioTherapeutics shareholders approve increase in authorized common shares from 144M to 185M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Certificate of Incorporation approved at reconvened 2023 Annual Meeting on July 13, 2023.","Authorized common shares increased by 41M, from 144M to 185M.","Votes: 33,870,055 for, 9,479,063 against, 1,042,433 abstentions.","Proposal passed with approximately 76% of votes cast in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290067,"accession_number":"0001558370-23-011550","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Protalix adjourns annual meeting to solicit votes for authorized share increase to 185M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Meeting approved election of 7 directors; votes ranged from 30.1M to 30.7M for, 2.2M to 2.7M withheld.","Stock plan amendment approved: shares available increased from 8.475M to 12.475M (25.8M for, 6.9M against).","Advisory vote on say-on-pay frequency favored one year (30.3M votes); board adopts annual frequency.","Meeting adjourned to July 13, 2023 to solicit more votes for charter amendment increasing authorized shares from 144M to 185M.","Ratification of PwC as auditor approved with 36.8M for, 2.7M against; broker non-votes existed on other items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290066,"accession_number":"0001558370-23-010565","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protalix announces FDA and EU approval of Elfabrio for Fabry disease; investor event June 27","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Elfabrio (pegunigalsidase alfa) approved in both US and EU for adult Fabry disease patients.","Commercial partner Chiesi Global Rare Diseases is prepared for launch.","In-person investor event scheduled for June 27, 2023 at Lotte Palace Hotel, New York City.","CEO Dror Bashan highlights ProCellEx platform and pipeline programs for future growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290065,"accession_number":"0001558370-23-010154","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2023-05-18T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Protalix receives $20M milestone from Chiesi after FDA approval of ELFABRIO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$20M milestone triggered by FDA approval of ELFABRIO (pegunigalsidase alfa-iwxj) for Fabry disease; payable within 30 days.","Proforma cash position including milestone is $51.6M as of May 18, 2023.","Protalix has received $95M total in upfront and development cost payments from Chiesi under two agreements.","Eligible for up to $1.0B in future regulatory and commercial milestones plus tiered royalties (15-40% US, 15-35% ex-US).","CEO Dror Bashan states the payment strengthens financial position; partner Chiesi has global commercial expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290064,"accession_number":"0001558370-23-008953","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves Protalix/Chiesi's ELFABRIO for Fabry disease in adults","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved ELFABRIO (pegunigalsidase alfa-iwxj) for adult Fabry disease patients.","ELFABRIO is a PEGylated enzyme replacement therapy with a half-life of 78.9 ± 10.3 hours.","More than 140 patients studied; head-to-head trial showed non-inferior efficacy to agalsidase beta in controlling eGFR decline.","Most common adverse reactions (≥15%): infusion reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity, sinusitis.","Protalix CEO says approval is a testament to team dedication; Chiesi offers alternative treatment option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290063,"accession_number":"0001558370-23-008188","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"European Commission approves Protalix's PRX-102 for Fabry disease in EU","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EC granted marketing authorization to PRX-102 (pegunigalsidase alfa) for adult Fabry disease patients.","Approval based on clinical program in >140 patients with up to 7.5 years of treatment.","PRX-102 showed non-inferior efficacy to agalsidase beta in controlling kidney disease (eGFR decline).","PRX-102 is not yet approved by FDA; U.S. review ongoing.","Partner Chiesi Global Rare Diseases will commercialize in the EU."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290062,"accession_number":"0001558370-23-007978","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protalix Q1 net loss $3.1M on revenue decline; positive CHMP opinion for PRX-102","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from goods fell 43% to $5.1M; license and R&D revenue down 37% to $4.5M.","Net loss of $3.1M ($0.05/sh) vs $2.3M loss in Q1 2022; cash $33.0M.","Feb 24, 2023: CHMP positive opinion recommending EU approval of PRX-102 for Fabry disease.","First patient dosed in Phase I trial of PRX-115 (PEGylated uricase) for severe gout.","Voluntary delisting from Tel Aviv Stock Exchange effective March 22, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":9588000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311016,"accession_number":"0001558370-23-002104","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Protalix BioTherapeutics enters $20M at-the-market equity offering with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM offering of up to $20M of common stock via H.C. Wainwright & Co. as sales agent.","Proceeds for general corporate purposes, including working capital and clinical trials.","Shares sold on NYSE American at prevailing market prices in 'at the market' transactions.","Agreement supplements existing July 2021 ATM facility (amended May 2022).","Offered under existing shelf registration statement (Form S-3, No. 333-264394)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311015,"accession_number":"0001558370-23-002100","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protalix FY2022 net loss narrows to $14.9M; CHMP positive opinion for PRX-102; FDA PDUFA May 9","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.9M ($0.31/share) vs $27.6M ($0.62/share) in FY2021; revenue from goods up 51% to $25.3M.","EMA CHMP adopted positive opinion recommending marketing authorization for PRX-102 (pegunigalsidase alfa) for Fabry disease; EC decision expected May 2023.","FDA accepted resubmitted BLA for PRX-102 with PDUFA action date of May 9, 2023; milestone payment from Chiesi if approved.","Cash and equivalents $22.2M at Dec 31, 2022; voluntary delisting from Tel Aviv Stock Exchange effective March 22, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":47638000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311014,"accession_number":"0001558370-23-001975","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Protalix and Chiesi receive positive CHMP opinion for PRX-102 (pegunigalsidase alfa) for Fabry disease","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP adopted positive opinion recommending marketing authorization for PRX-102 (pegunigalsidase alfa) for adult Fabry disease patients.","PRX-102 is the first and only pegylated enzyme replacement therapy for Fabry disease.","Clinical program includes Phase 3 BALANCE, BRIDGE, BRIGHT trials with over 400 years of exposure.","Final European Commission decision on MAA expected in early May 2023.","Protalix (PLX) and Chiesi Global Rare Diseases (Chiesi Group) collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311013,"accession_number":"0001558370-23-000003","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protalix updates on PRX-102 FDA PDUFA date May 9, 2023; PRX-115 Phase I in Q1 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MAA submitted to EMA Feb 2022; BLA resubmitted to FDA Nov 2022 with PDUFA goal date May 9, 2023.","BALANCE study: PRX-102 statistically non-inferior to agalsidase beta on eGFR slope; BRIGHT: stable disease.","PRX-115 (PEGylated uricase) for severe gout: Phase I trial planned for Q1 2023; preclinical data show stable PK and low immunogenicity.","If PRX-102 approved by FDA, Protalix eligible for milestone payment from partner Chiesi."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329637,"accession_number":"0001558370-22-018990","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2022-12-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Protalix BioTherapeutics sets March 22, 2023 for TASE delisting; will remain on NYSE American","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Delisting from Tel Aviv Stock Exchange effective March 22, 2023; last trading day March 20, 2023.","Common stock will continue to be listed and trade on NYSE American under symbol PLX.","Israeli shareholders urged to contact their brokers to transfer shares to a NYSE American-based account."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329636,"accession_number":"0001558370-22-018894","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2022-12-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Protalix BioTherapeutics voluntarily delists from Tel Aviv Stock Exchange; NYSE American listing unaffected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Company requested immediate delisting of common stock from TASE; effective three months from request.","Stock continues trading on TASE during the three-month period; all shares expected to transfer to NYSE American.","NYSE American listing and SEC reporting obligations remain unchanged; company will focus on U.S. capital market.","Decision aims to reduce operating costs by having a single set of listing rules and regulations.","No financial impact disclosed; delisting is voluntary and procedural."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329635,"accession_number":"0001558370-22-017549","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Protalix resubmits BLA for PRX-102 for Fabry disease; Q3 revenue up 96% YoY","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BLA resubmitted to FDA on Nov 9, 2022; FDA review expected within six months; milestone payment due upon approval.","Q3 2022 revenue from selling goods $8.8M up 96% YoY; net loss $3.6M ($0.07/share) vs loss $4.2M ($0.09).","Cash and equivalents $20.8M as of Sep 30, 2022.","BLA includes data from over 140 patients, phase III BALANCE, BRIDGE, BRIGHT studies, and phase I/II extension.","Chiesi Global Rare Diseases is commercialization partner; EMA also reviewing MAA for PRX-102."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347202,"accession_number":"0001558370-22-014127","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2022-09-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Protalix BioTherapeutics enters fill/finish deal with Chiesi for PRX-102 launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Chiesi for commercial fill/finish services for PRX-102 (Fabry disease candidate).","Protalix to supply drug substance; Chiesi will provide fill/finish services for global launch.","Term through Dec 31, 2025, renewable for 7 years by mutual agreement.","Letter Agreement modifies License Agreements to establish Chiesi as supplier and potential alternate source.","Agreement supports anticipated launch; no financial terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347201,"accession_number":"0001558370-22-013557","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protalix Q2 net loss narrows to $5.3M; PRX-102 Phase III CSR complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $8.8M ($3.4M product sales +$5.4M license/R&D), up 38% YoY.","Net loss $5.3M ($0.11/share) vs. $11.2M ($0.25/share) in Q2 2021.","Cash and equivalents $28.6M at June 30, 2022.","Phase III BALANCE trial CSR confirms positive topline results for PRX-102 in Fabry disease.","Appointed Shmuel Ben Zvi, Ph.D. to Board as Audit Committee Chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":24838000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363619,"accession_number":"0001558370-22-010491","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2022-06-30T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Protalix appoints Shmuel Ben Zvi to board; stockholders approve share increase to 144M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Shmuel Ben Zvi appointed as independent director, joining Audit and Compensation Committees.","Stockholders approved amendment to increase authorized common shares from 120M to 144M.","Stockholders approved 2006 Stock Plan amendment raising available shares from ~5.7M to ~8.5M.","Advisory vote on executive compensation passed with ~80% of votes cast in favor.","All six director nominees elected; Kesselman & Kesselman ratified as auditor for FY2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363618,"accession_number":"0001558370-22-009406","cik":1006281,"company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","form_type":"8-K","filed_at":"2022-05-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protalix announces five poster presentations at Fabry Disease conference","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Posters cover pegunigalsidase alfa data from BALANCE, BRIDGE, BRIGHT, and extension studies.","Conference is the 7th Update on Fabry Disease in Würzburg, Germany, May 29-31, 2022.","Posters and abstracts will be posted on Protalix's website under Investors/Presentations.","Data include 24-month renal function results from Phase III BALANCE study.","No specific efficacy or safety numbers were disclosed in the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":174034733.4339623,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-26T23:59:59+00:00|363618"}